Harrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including the nationâs leading ophthalmology pharmaceutical compounding business, ImprimisRx. The company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals and Radley Pharmaceuticals, companies founded as subsidiaries of Harrow Health. The Company also owns royalty rights in certain 505(b)(2) drug candidates being developed by Eton, Surface, Melt, Mayfield and Radley. Harrow intends to create, invest in and grow paradigm shifting health care businesses that put patients first. Source
No articles found.
ArQule is a biopharmaceutical company engaged in the research and development of t...
ArQule is a biopharmaceutical company engaged i...
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight mu...
Gritstone Oncology is developing tumor-specific...
Founded on September 28, 2005 through the merger of Daiichi Pharmaceutical and San...
Founded on September 28, 2005 through the merge...
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers...
Gilead Sciences, Inc. is a research-based bioph...
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global ...
Celgene Corporation, headquartered in Summit, N...
Join the National Investor Network and get the latest information with your interests in mind.